Coya Therapeutics (COYA) Net Cash Flow (2022 - 2026)

Coya Therapeutics (COYA) has 5 years of Net Cash Flow data on file, last reported at $3.9 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 238.9% year-over-year to $3.9 million; the trailing twelve-month figure through Mar 2026 stood at $15.7 million (up 3524.29% YoY), and the FY2025 full-year result was $8.5 million, up 48.49% from the prior year.
• Net Cash Flow retreated to $3.9 million in Q1 2026, from $18.7 million in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $21.7 million in Q4 2023 to a low of -$5.8 million in Q2 2025.
• A 5-year average of $2.8 million and a median of -$1.1 million in 2025 frame the typical range for Net Cash Flow.
• Across the five-year window, Net Cash Flow surged 900.12% in 2023 and plunged 1085.74% in 2025, its largest moves.
• Tracing COYA's Net Cash Flow over 5 years: stood at -$2.7 million in 2022, then surged by 900.12% to $21.7 million in 2023, then tumbled by 66.5% to $7.3 million in 2024, then surged by 156.69% to $18.7 million in 2025, then slumped by 79.13% to $3.9 million in 2026.
• Business Quant data shows COYA's Net Cash Flow at $3.9 million in Q1 2026, $18.7 million in Q4 2025, and -$1.1 million in Q3 2025.